Abiopharma

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Charlottes Web Reports Q3 2025 Results

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease

Ovid Therapeutics Inc. - Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results